Autoimmune Disorders Of The Eyelid In Ocular Surface Disease: From Molecular Pathways To Precision Therapy

Autoimmune disorders involving the eyelid skin represent an underrecognized but clinically significant contributor to ocular surface instability. The eyelid constitutes a critical anatomical and immunological interface within the ocular surface unit. Chronic periocular inflammation may precede systemic autoimmune disease and lead to meibomian gland dysfunction, tear film instability, conjunctival scarring, and vision-threatening complications. This study aims to integrate current molecular insights with clinical implications relevant to ocular surface specialists.

Narrative literature review conducted at a university hospital

This study is a narrative literature review synthesizing current data from ophthalmology, dermatology, and immunology. Peer-reviewed publications addressing autoimmune diseases with eyelid involvement—including ocular cicatricial pemphigoid, pemphigus vulgaris, bullous pemphigoid, thyroid-associated orbitopathy, systemic lupus erythematosus, and Sjögren’s syndrome—were analyzed.

Particular focus was placed on:

• Cytokine and T helper cell pathways (Th1, Th2, Th17)

• Autoantibody-mediated complement activation

• Fibroblast-driven tissue remodeling

• Tear proteomics and molecular biomarkers

• Advanced imaging (IVCM, AS-OCT)

• Emerging biologic and targeted therapies

Autoimmune eyelid inflammation is driven by cytokine imbalance and autoantibody-mediated complement activation, promoting fibrosis, vascular remodeling, and meibomian gland dysfunction with subsequent tear film instability. In ocular cicatricial pemphigoid, progressive conjunctival scarring leads to entropion, trichiasis, and corneal damage. In thyroid-associated orbitopathy, fibroblast activation and adipogenesis result in eyelid retraction and exposure-related ocular surface disease. Lupus and Sjögren’s syndrome further impair tear homeostasis through immune complex deposition and glandular infiltration. Emerging biomarkers and targeted biologics support precision-based periocular management and earlier therapeutic intervention.

Autoimmune-mediated eyelid inflammation should be recognized as a clinically relevant component of ocular surface disease rather than an isolated dermatologic manifestation. Molecular characterization of inflammatory pathways enables a transition from broad immunosuppression to precision, biomarker-guided therapy.

Integration of advanced diagnostics, targeted biologics, and personalized management strategies may significantly improve outcomes and prevent irreversible ocular surface damage in patients with autoimmune periocular disease.